Flutamide Withdrawal and Concomitant Initiation of Aminoglutethimide in Patients with Hormone Refractory Prostate Cancer

This publication has 12 references indexed in Scilit:

• Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables
  Cancer, 1995
• Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
  New England Journal of Medicine, 1995
• Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer
  The American Journal of Medicine, 1995
• Surprising Activity of Flutamide Withdrawal, When Combined With Aminoglutethimide, in Treatment of "Hormone-Refractory" Prostate Cancer
  JNCI Journal of the National Cancer Institute, 1994
• Androgen receptor gene mutations in human prostate cancer
  The Journal of Steroid Biochemistry and Molecular Biology, 1993
• A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgens
  Biochemical and Biophysical Research Communications, 1990
• A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
  New England Journal of Medicine, 1989
• Analysis of the androgenic activity of synthetic “progestins” currently used for the treatment of prostate cancer
  The Journal of Steroid Biochemistry and Molecular Biology, 1987
• Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate
  Molecular and Cellular Endocrinology, 1985
• New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens
  The Prostate, 1983